SEC 13F Intelligence

Managers / Q2 2022 · view latest →

Vida Ventures Advisors, LLC

CIK 0001831423 · 40 BROAD STREET, SUITE 201, BOSTON, MA, 02109 · 6176489100

Reported Value
$118M
Q2 2022
Positions
8
Filings on Record
21
2019–present window
Filed
Jul 15, 2022
original filing

Summary

Vida Ventures Advisors, LLC reported $118M in U.S.-listed holdings across 8 positions for Q2 2022.

The portfolio is heavily concentrated: KNTEUSD alone accounts for 29.3% of reported value.

The book was largely unchanged from Q1 2022.

Portfolio Metrics

Turnover
+5.4%
vs prior filed quarter
Largest Position
+29.3%
Kinnate Biopharma

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q3 ’20: $160MQ3 ’20Q4 ’20: $487MQ1 ’21: $396MQ2 ’21: $399MQ2 ’21Q3 ’21: $349MQ4 ’21: $267MQ1 ’22: $172MQ1 ’22Q2 ’22: $118MQ3 ’22: $111MQ4 ’22: $74MQ4 ’22Q1 ’23: $73MQ2 ’23: $77MQ3 ’23: $65MQ3 ’23Q4 ’23: $84MQ1 ’24: $180MQ2 ’24: $91MQ2 ’24Q3 ’24: $139MQ4 ’24: $146MQ1 ’25: $14MQ1 ’25Q2 ’25: $16MQ3 ’25: $29Mfilingsflow.com

Portfolio Composition

By security type
Common Stock: 73.6%ADR: 20.3%Other: 6.1%
  • Common Stock · 73.6% · $87M
  • ADR · 20.3% · $24M
  • Other · 6.1% · $7M

Quarter-over-Quarter Changes full breakdown →

vs Q1 2022 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
Praxis Precision Medicines, Inc.HELD+02.94M−$23M$7M
260Centessa Pharmaceuticals plcHELD+03.93M−$16M$19M
KRON1USDKronos Bio, Inc.HELD+02.77M−$10M$10M
DYNDyne Therapeutics, Inc.HELD+02.96M−$8M$20M
ALLOAllogene Therapeutics, Inc.HELD+01.80M+$4M$20M
KNTEUSDKinnate Biopharma, Inc.HELD+02.75M+$4M$35M
LIANYLianBioHELD+02.28M−$4M$5M
Homology Medicines, Inc.HELD+0770.8K−$824,000$2M

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q2 2022

8 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1KNTEUSDKinnate Biopharma, Inc.history →Common Stock29.28%$35M2.75M
2ALLOAllogene Therapeutics, Inc.history →Common Stock17.32%$20M1.80M
3DYNDyne Therapeutics, Inc.history →Common Stock17.18%$20M2.96M
4260Centessa Pharmaceuticals plchistory →Ordinary Shares16.18%$19M3.93M
5KRON1USDKronos Bio, Inc.history →Common Stock8.51%$10M2.77M
6Praxis Precision Medicines, Inc.Common Stock6.08%$7M2.94M
7LIANYLianBiohistory →Ordinary Shares4.17%$5M2.28M
8Homology Medicines, Inc.Common Stock1.28%$2M770.8K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q3 2025$29M2Nov 3, 202513F-HRchanges · EDGAR ↗
Q2 2025$16M2Jul 10, 202513F-HRchanges · EDGAR ↗
Q1 2025$14M3Apr 3, 202513F-HRchanges · EDGAR ↗
Q4 2024$146M6Jan 21, 202513F-HRchanges · EDGAR ↗
Q3 2024$139M6Oct 8, 202413F-HRchanges · EDGAR ↗
Q2 2024$91M5Jul 10, 202413F-HRchanges · EDGAR ↗
Q1 2024$180M5Apr 12, 202413F-HRchanges · EDGAR ↗
Q4 2023$84M7Jan 5, 202413F-HRchanges · EDGAR ↗
Q3 2023$65M8Oct 3, 202313F-HRchanges · EDGAR ↗
Q2 2023$77M7Jul 19, 202313F-HRchanges · EDGAR ↗
Q1 2023$73M7Apr 13, 202313F-HRchanges · EDGAR ↗
Q4 2022$74M7Feb 8, 202313F-HRchanges · EDGAR ↗
Q3 2022$111M8Oct 5, 202213F-HRchanges · EDGAR ↗
Q2 2022$118M8Jul 15, 202213F-HRchanges · EDGAR ↗
Q1 2022$172M8May 4, 202213F-HRchanges · EDGAR ↗
Q4 2021$267M8Feb 10, 202213F-HRchanges · EDGAR ↗
Q3 2021$349M8Nov 12, 202113F-HRchanges · EDGAR ↗
Q2 2021$399M9Aug 12, 202113F-HRchanges · EDGAR ↗
Q1 2021$396M8May 11, 202113F-HRchanges · EDGAR ↗
Q4 2020$487M8Feb 12, 202113F-HRchanges · EDGAR ↗
Q3 2020$160M5Nov 12, 202013F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.